Cornercap Investment Counsel Inc Macrogenics Inc Transaction History

Cornercap Investment Counsel Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	SELL	$3.31 - $18.51 $635 - $3,553	-192 Reduced 1.18%	16,025 $68,000
Q1 2024 May 10, 2024	SELL	$9.77 - $21.47 $125,964 - $276,812	-12,893 Reduced 44.29%	16,217 $238,000
Q4 2023 Jan 30, 2024	SELL	$4.48 - $10.11 $27,923 - $63,015	-6,233 Reduced 17.64%	29,110 $280,000
Q3 2023 Nov 13, 2023	SELL	$4.48 - $6.19 $1,747 - $2,414	-390 Reduced 1.09%	35,343 $164,000
Q2 2023 Aug 11, 2023	SELL	$4.62 - $7.54 $72,755 - $118,739	-15,748 Reduced 30.59%	35,733 $191,000
Q1 2023 May 11, 2023	SELL	$4.82 - $7.24 $1,084 - $1,629	-225 Reduced 0.44%	51,481 $369,000
Q4 2022 Feb 13, 2023	SELL	$3.34 - $6.98 $14,131 - $29,532	-4,231 Reduced 7.56%	51,706 $346,000
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $87,961 - $152,544	29,223 Added 109.39%	55,937 $194,000
Q2 2022 Aug 15, 2022	BUY	$2.25 - $9.99 $60,106 - $266,872	26,714 New	26,714 $79,000

132

55.4M

215K

238K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $200M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Cornercap Investment Counsel Inc, based on Form 13F filings with the SEC.

Stay updated on Cornercap Investment Counsel Inc with notifications on news.